Chronic kidney disease-mineral and bone disorder (CKDMBD) is common in kidney transplant recipients (KTRs), where secondary hyperparathyroidism (HPTH) and posttransplantation bone disease (PTBD) are potential effectors of both graft and vascular aging. Reduced 25(OH)D levels are highly prevalent in KTRs. Experimental and clinical evidence support the direct involvement of deranged vitamin D metabolism in CKD-MBD among KTRs. This review analyzes the pathophysiology of vitamin D derangement in KTRs and its fall out on patient and graft outcome, highlighting the roles of both nutritional and active vitamin D compounds to treat PTBD, cardiovascular disease (CVD) and graft dysfunction. Fibroblast growth factor-23-parathyroid hormone (PTH)-vitamin D axis, immunosuppressive therapy and previous bone status have been associated with PTBD. Although several studies reported reduced PTH levels in KTRs receiving nutritional vitamin D, its effects on bone mineral density (BMD)
Cianciolo, G., Galassi, A., Capelli, I., Angelini, M.l., La Manna, G., Cozzolino, M. (2016). Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy. AMERICAN JOURNAL OF NEPHROLOGY, 43(6), 397-407 [10.1159/000446863].
Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy
CIANCIOLO, GIUSEPPE;CAPELLI, IRENE;ANGELINI, MARIA LAURA;LA MANNA, GAETANO;
2016
Abstract
Chronic kidney disease-mineral and bone disorder (CKDMBD) is common in kidney transplant recipients (KTRs), where secondary hyperparathyroidism (HPTH) and posttransplantation bone disease (PTBD) are potential effectors of both graft and vascular aging. Reduced 25(OH)D levels are highly prevalent in KTRs. Experimental and clinical evidence support the direct involvement of deranged vitamin D metabolism in CKD-MBD among KTRs. This review analyzes the pathophysiology of vitamin D derangement in KTRs and its fall out on patient and graft outcome, highlighting the roles of both nutritional and active vitamin D compounds to treat PTBD, cardiovascular disease (CVD) and graft dysfunction. Fibroblast growth factor-23-parathyroid hormone (PTH)-vitamin D axis, immunosuppressive therapy and previous bone status have been associated with PTBD. Although several studies reported reduced PTH levels in KTRs receiving nutritional vitamin D, its effects on bone mineral density (BMD)I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.